Trials targeting PD-1/PD-L1 (e.g., CheckMate 143) and CTLA-4 have demonstrated limited clinical benefit in unselected GBM populations, largely due to the profoundly immunosuppressive tumor microenvironment [63]. This evidence concerns the gene CTLA4 and neoplasm.